Clinical efficacy of Qiliqiangxin capsule combined with sacubatrovalsartan sodium in the treat-ment of chronic heart failure and its effect on cardiac function
Clinical efficacy of Qiliqiangxin capsule combined with sacubatrovalsartan sodium in the treat-ment of chronic heart failure and its effect on cardiac function
Objective To explore the clinical effect of Qiliqiangxin capsule combined with sacubatro valsartan sodium in the treatment of chronic heart failure.Methods 98 patients with chronic heart failure from September 2020 to March 2022 were randomly divided into two groups.Both groups were treated with routine treatment.On this basis,the control group(n=49)was treated with sacubatrovalsartan sodium,and the observation group(n=49)was treated with Qiliqiangxin capsule on the basis of the control group.Both groups were treated for 2 months.The clinical efficacy,cardiac function inde-xes[left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDd),left ventricular end systolic diameter(LVESD),ventricular septal thickness(IVS),left atrial diameter(LAD)],serum brain natriuretic peptide(BNP),high-sensitivity troponin(HS TNT),matrix metalloproteinase-2(MMP-2)]and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.92％,higher than 83.67％of the control group(P＜0.05).After treatment,LVEF(52.86±9.56)in the observation group was higher than that in the control group(41.89±8.12),LVEDd(57.03±9.02)mm,LVESD(46.33±9.87)mm,IVS(9.18±0.75)mm and LAD(34.24± 2.72)mm,all lower than those in the control group(P＜0.05).In the observation group,BNP was(260.86±24.56)ng/l,HS TNT was(150.03±17.02)ng/l and MMP-2 was(189.71±11.23)ng/l after treatment μg/l was lower than that of the control group(P＜0.05).There was no difference in adverse reactions between the two groups(P＞0.05).Conclusion Compared with the simple treatment of chronic heart failure with sacubatrovalsartan sodium,the combined treatment with Qiliqiangxin capsule can improve the clinical efficacy,improve the serological indexes and cardiac function,promote the re-covery of patients,and have better safety.
维普
万方数据